Orexo’s annual report for 2012 released

Orexo’s annual report for the 2012 fiscal year has been published and can be
downloaded from investor section of the company’s homepage
www.orexo.com (http://www.orexo.com/en/Investor-Relations/Interim-reports/).

For further information, please contact:
Beata Augenblick, Investor Relations
Tel: +46-18 780 88 50
E-mail: beata.augenblick@orexo.com

About Orexo
Orexo AB is an emerging specialty pharma company developing improved treatments
using proprietary drug delivery technology. Orexo’s expertise is within the area
of reformulation technologies and especially sublingual formulations. The
company has a portfolio of revenue generating EU and US approved products
currently marketed under licence and a pipeline of several reformulations of
approved compounds for areas of unmet medical need. Orexo also has collaboration
projects with several international pharma companies. Orexo AB is headquartered
in Sweden has 90 employees and is listed on NASDAQ-OMX. The largest shareholders
are Novo A/S and HealthCap. For information about Orexo, please visit
www.orexo.com.

Orexo is required under the Financial Instruments Trading Act to make the
information in this press release public. The information was submitted for
publication at 1:30pm CET on March 21, 2013.